Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 20 Show results per page	View Search Criteria \| Help With Results


1.		Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				EFC6546 AVE0005, NCT00519285


2.		A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Pharmaceutical / Industry				EFC10261 AVE0005, EudraCT 2007-000819-29, NCT00532155


3.		Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in theTreatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				EFC10262 EudraCT 2007-000820-42, NCT00561470


4.		Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				EFC10547 AVE0005, EudraCT 2007-003476-19, NCT00574275

Last Modified: 6/8/2007 First Published: 2/12/2007


5.		Phase I/II Study of VEGF Trap and Docetaxel in Patients With Persistent or Recurrent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				MDA-2006-0329 7757, NCT00436501


6.		A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				VGFT-ST-0708 TCD10767, NCT00794417

Last Modified: 1/14/2009 First Published: 7/23/2006


7.		Phase II Randomized Study of VEGF Trap in Patients With Metastatic or Unresectable Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				ECOG-E4805 E4805, NCT00357760

Last Modified: 11/12/2008 First Published: 8/18/2006


8.		Phase II Study of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				NABTC-0601 NCT00369590

Last Modified: 12/10/2008 First Published: 10/14/2006


9.		Phase II Study of VEGF Trap in Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				PMH-PHL-051 7502, NCI-7502, NCT00390234

Last Modified: 5/22/2008 First Published: 2/12/2007


10.		Phase II Study of VEGF Trap in Patients With Relapsed or Refractory, Stage II or III Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NYWCCC-0608008688 7521, NCT00437034

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute